ONGOING RESEARCH STUDIES IN THE NEUROSCIENCES PROGRAM

Quarterly Report on the Research Activities Involving a Clinical Research Coordinator

October 1st, 2015 – December 31st, 2015

Prepared by

Mr. Ivan Despot

Clinical Research Coordinator
Division of Neurosurgery
Clinical Academic Campus of Vancouver General Hospital
University of British Columbia

December 22nd, 2015
Table of Contents:

1. INTRODUCTION..............................................................................................................3

2. ONGOING PROSPECTIVE STUDIES ..................................................................................4
   1. Timing of Mobilization After Burr Hole Drainage of Chronic Subdural Haematomas: a randomized study .......... 4
   2. AHCRN REGISTRY ......................................................................................................... 4
   3. Resident Activity Tracker Evaluation Study ........................................................................ 5
   4. TOCA 511 Study ............................................................................................................ 6
   5. Quality of life in patients diagnosed with unruptured cerebral aneurysm: prospective single-center series .......... 6

3. ONGOING RETROSPECTIVE STUDIES .........................................................................8
   1. Biomarkers in Malignant Brain Tumors Study ................................................................. 8
   2. LAANTERN Registry ........................................................................................................ 8
   3. Quality of Life after Surgery in Patients with Pituitary Tumors and Acromegaly .............. 9

4. INACTIVE OR COMPLETE STUDIES .............................................................................10
   1. Thromboprophylaxis in Traumatic Brain Injury Study ...................................................... 10
   2. Perioperative Quality of Life in Patients with Cushing’s Disease ..................................... 10
   3. Timing of Incidence and Recovery of Delayed Facial Palsy after vestibular schwannoma resection: a retrospective review .......................................................... 10

5. SUMMER STUDENTS .....................................................................................................12
   1. Collection and Submission of Clinical, CSF and Radiological Data of Patients Being Assessed at Vancouver General Hospital Adult Hydrocephalus Clinic as Part of the Adult Hydrocephalus Clinical Research Network (AHCRN) .........................................................................................12
1. INTRODUCTION

This report contains up to date information on the ongoing research projects that are supported by the Clinical Research Coordinator (CRC) of the University of British Columbia’s (UBC’s) Division of Neurosurgery at the Clinical Academic Campus of Vancouver General Hospital (VGH) for the period of October 1st – December 31st, 2015. The main objective of the report is to familiarize the staff of the Division of Neurosurgery of UBC with the current research activities that are being supported by their CRC. The studies that are supported by the CRC in this report are divided into two categories of ongoing studies: prospective studies, and retrospective studies. Additionally, summer student research projects that have applied for funding are included as their own section. The number of studies per category is presented in the table below (Table 1).

Table 1. Number of studies per category.

<table>
<thead>
<tr>
<th>Number of Ongoing Studies</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prospective</td>
<td>5</td>
</tr>
<tr>
<td>Retrospective</td>
<td>3</td>
</tr>
<tr>
<td>Inactive or Complete Studies</td>
<td>3</td>
</tr>
<tr>
<td>Summer Studentships</td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td>12</td>
</tr>
</tbody>
</table>

Detailed description of the purpose, objective, budget and sample size of each study supported by the CRC is presented in the next three sections of this report.
2. ONGOING PROSPECTIVE STUDIES

1. Timing of Mobilization After Burr Hole Drainage of Chronic Subdural Haematomas: a randomized study – PI: Dr. Akagami

<table>
<thead>
<tr>
<th>Funding</th>
<th>Source</th>
<th>Amount</th>
<th>Study period</th>
<th>Anticipated enrolment</th>
<th># of subjects enrolled</th>
<th>Approvals</th>
<th>Status</th>
<th>Abstract/Paper/Manuscript</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>Sep ‘14</td>
<td>142</td>
<td>42</td>
<td>Obtained</td>
<td>Active</td>
<td>N/A</td>
</tr>
</tbody>
</table>

This is a two treatment arm, randomized, prospective study to minimize re-do burr-hole drainage procedures and any other associated complications in patients with chronic subdural haematomas.

Primary Outcomes:
- Recurrence requiring re-do drainage within the 1st month post-operatively
- Recurrence requiring re-do drainage between the 1st and 3rd months post-operatively

The timing of when to mobilize patients after burr-hole drainage of chronic subdural haematomas remains controversial. Traditionally, patients have been subjected to delayed mobilization in order to allow for the theoretical re-expansion of the brain and to decrease recurrence. Timing of bed rest is not consistent among centres and varies from immediately after to 7 days after surgery.

The objective is to determine optimal timing of mobilization in CSDH patients following a burr-hole drainage.

There are 42 participants enrolled in the CSDH Study, 6 of which were enrolled during the last quarter.


<table>
<thead>
<tr>
<th>Funding</th>
<th>Source</th>
<th>Amount</th>
<th>Study period</th>
<th>Anticipated enrolment</th>
<th># of subjects enrolled</th>
<th>Approvals</th>
<th>Status</th>
<th>Abstract/Paper/Manuscript</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>Nov ‘14</td>
<td>perpetual</td>
<td>42</td>
<td>obtained</td>
<td>active</td>
<td>N/A</td>
</tr>
</tbody>
</table>

A multicenter and multinational registry that collects data on adult hydrocephalus patients to characterize the etiology, understand variability, progression, and current treatment practices for hydrocephalus patients.

The overall purpose of the Registry is to establish and maintain a hydrocephalus patient event database for the Clinical Centers of the AHCNRN, a research network newly established to investigate clinical management of adult hydrocephalus.

Primary Objectives:
- To describe the natural history and treatment response for adults with previously untreated congenital hydrocephalus
- To describe the assessment and treatment of patients with Normal Pressure Hydrocephalus (NPH)
- To describe the complications associated with shunt surgery
- To determine the role for treatment with Endoscopic Third Ventriculostomy (ETV)

The Registry will provide previously unavailable epidemiological information about hydrocephalus patients seen throughout the participating Clinical Centers. This information will provide the basis for multi-institutional studies to be carried out by the AHCNRN that may ultimately improve the clinical care for adults with hydrocephalus throughout the world. The continuing collection of such information serves to provide data necessary for hypothesis generation and study design. Examples of preliminary study designs include, but are not limited to, the following: preliminary power analysis, sample size determination, and recruitment projections. Radiologic imaging data will provide a unique opportunity to assess aspects of adult hydrocephalus diagnosis, management, and outcomes.

**Accomplishments of Merit:**

- VGH made UBC 1st site to have accomplish Neuropsychological Battery Administration Training
- VGH made UBC 1st site to complete Neuropsychological Battery Administration Quality Control

*There are 187 participants enrolled in the AHCNRN Registry at all participating sites. Of those, 42 are from the VGH site with 11 patients enrolled in the last quarter.*

### 3. Resident Activity Tracker Evaluation Study - PI: Dr. Toyota

<table>
<thead>
<tr>
<th>Funding</th>
<th>Source</th>
<th>Amount</th>
<th>Study period</th>
<th>Anticipated enrolment</th>
<th># of subjects enrolled</th>
<th>Approval</th>
<th>Status</th>
<th>Abstract/Paper/Manuscript</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>RDBC</td>
<td></td>
<td>Sep 15 - Aug 16</td>
<td>60</td>
<td>35</td>
<td>Yes</td>
<td>Active</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Medical resident work hour restrictions remains a large topic of debate in the Accreditation Council for Graduate Medical Education; and more importantly, also in the Royal College of Physicians and Surgeons of Canada.

An adequate number of hours of sleep play an important role in medical residents’ performance, and quality of life. Factors associated with medical resident fatigue and prolonged work hours include the following: an increase in automobile accidents, negative effect on well-being, an increase in stress, relationship-related stress, and decreased performance in both simulated tasks and standardized tests. Formal changes to resident work-hours regulation have not been imposed for Canadian medical residents. On-call duties vary substantially across medical specialties further complicating the issue. The actual physical demands of resident on-call duties and the impact on sleep duration and number of interruptions have not been comprehensively investigated to date.

This study will be the first in literature to measure average and maximum heart rate, sleep duration and interruptions, and number of steps taken per day in medical resident trainees, across non-surgical and surgical specialties and when the residents are on or off call. Such novel results will help advance and guide current discussion on resident work hour restriction towards a more comprehensive conclusion.
There are 35 residents currently enrolled in the RATE Study, 22 of which were enrolled during the last quarter.

4. **TOCA 511 Study** - A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma – PI: Dr. Toyota

<table>
<thead>
<tr>
<th>Funding</th>
<th>Source</th>
<th>Amount</th>
<th>Study period</th>
<th>Anticipated enrolment</th>
<th># of subjects enrolled</th>
<th>Approvals</th>
<th>Status</th>
<th>Abstract/ Paper/ Manuscript</th>
</tr>
</thead>
<tbody>
<tr>
<td>Finalized</td>
<td>Tocagen</td>
<td>N/A</td>
<td>01/10/15-30/09/19 (Enroll)</td>
<td>170 in Phase 2; 200 in Phase 3</td>
<td>N/A</td>
<td>Pending</td>
<td>Ethics review</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Name of Investigational Product: Toca 511, a retroviral replicating vector (RRV) expressing a yeast-derived, codon-optimized cytosine deaminase (CD) prodrug-activator gene, in combination with Toca FC (flucytosine) extended-release tablets.

Methodology: This is a multicenter, randomized, open-label study of Toca 511 and Toca FC versus standard of care (SOC) that comprises Investigator's choice of either single agent chemotherapy (lomustine or temozolomide) or bevacizumab administered to subjects undergoing resection for first or second recurrence (including this recurrence) of glioblastoma or anaplastic astrocytoma. Subjects will be randomized at the time of surgery in a 1:1 ratio to receive either Toca 511 and Toca FC or control. Repeat scans will be obtained every 6 weeks for the first year and every 3 months after that.

The ethics application has been submitted.

5. **Quality of life in patients diagnosed with unruptured cerebral aneurysm: prospective single-center series** – Dr. Gooderham – *New this quarter*

<table>
<thead>
<tr>
<th>Funding</th>
<th>Source</th>
<th>Amount</th>
<th>Study period</th>
<th>Anticipated enrolment</th>
<th># of subjects enrolled</th>
<th>Approvals</th>
<th>Status</th>
<th>Abstract/ Paper/ Manuscript</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>N/A</td>
<td>N/A</td>
<td>Jan 2016 – Dec 2017</td>
<td>150</td>
<td>N/A</td>
<td>Pending</td>
<td>Pre-submission</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Aneurysms may require endovascular or microsurgical treatment if ruptured, growing, symptomatic or of significant size. The goal of prophylactic treatment of an aneurysm is to increase the number of years with good quality of life.

The main goal of the present study is to identify how does the diagnosis of an unruptured cerebral aneurysm and its subsequent treatment impact quality of life as measured by SF-36 and EQ5D in patients. We aim to quantify if the impact in quality of life varies overtime. We aim to verify if the choice of technique (endovascular vs microsurgical) has an impact on quality of life in the short and long term. We will explore the relationship with other variables such as gender, medical comorbidities, aneurysm location, and postoperative complications.
Quality of life will be assessed via the SF-36 and the EQ5D tool at time 0 (time of diagnosis) and at 1 year for patients with an untreated cerebral aneurysm. Quality of life will be assessed via the SF-36 tool at time 0 (time of diagnosis), 6-8 weeks postoperative follow-up and at 1-year postoperative follow-up in the patients who have been treated. The latter group will be divided in 2 sub-groups: endovascular and microsurgical (clipping).

Ultimately, we will compare quality of life in untreated unruptured cerebral aneurysms patients with general population at time 0 and 1 year. We will compare quality of life in coiled unruptured cerebral aneurysm patients at time 0, 6-8 weeks and at 1 year. We will compare quality of life in clipped unruptured cerebral aneurysm patients at time 0, 6-8 weeks and at 1 year. We will compare quality of life between clipped and coiled patients at time 0, 6-8 weeks and at 1 year.
3. ONGOING RETROSPECTIVE STUDIES

1. **Biomarkers in Malignant Brain Tumors Study - PI: Dr Toyota**

<table>
<thead>
<tr>
<th>Study period</th>
<th>Approvals UBC CREB/VCHRI</th>
<th>Charts reviewed /sample size</th>
<th>Status</th>
<th>Abstract/Paper/Manuscript</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>June 22, 2015 – August 1, 2016</td>
<td>Obtained</td>
<td>151/151</td>
<td>Active</td>
<td>N/A</td>
<td>None</td>
</tr>
</tbody>
</table>

**Objective:**

To conduct a retrospective clinical chart review of our institution’s glioblastoma cases to compare the predictive and prognostic value of molecular markers to that of traditional histological diagnoses.

This is a retrospective chart review involving charts of patients with glioblastoma treated at VGH from 2010-2014. We have created a database to register basic patient demographics, treatment protocols and outcome. Specific to our study, we classified the tumors by classic histologic description and grading as well as new cutting edge diagnostic molecular and genetic analysis.

Based on this database, we will stratify the patients into outcome categories based on classical grading and newer molecular markers. A statistical analysis of this data will then be conducted in order to compare the predictive value of these classic histologic methods with the newer methods for patient outcomes.

Quinn Parker was a summer student who had obtained UBC SSRP funding for the summer. The chart review has been completed, and we await statistical analysis.

2. **LAANTERN Registry - PI Dr. Toyota**

<table>
<thead>
<tr>
<th>Study period</th>
<th>Approvals UBC CREB/VCHRI</th>
<th>Anticipated Enrollment</th>
<th>Status</th>
<th>Abstract/Paper/Manuscript</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jan 2016 – Jan 2018</td>
<td>pre-submission</td>
<td>TBD</td>
<td>not started yet</td>
<td>N/A</td>
<td>Monteris</td>
</tr>
</tbody>
</table>

The NeuroBlate® System (NBS) is a minimally invasive robotic laser thermotherapy tool that is being manufactured by Monteris Medical. It employs a pulsed surgical laser to deliver targeted energy to abnormal brain tissue. To further understand performance and utilization of NBS in current standard of care, post-market multi-center registry called LAANTERN (Laser Ablation of Abnormal Neurological Tissue using Robotic Neuroblate system) is designed to collect baseline, procedural and follow-up data on patients that are already scheduled to be treated with NBS in observational manner for publication purposes.

This is a multi-center registry that will include data collection at baseline (prior to NeuroBlate® procedure, which is also referred as the index procedure), during index procedure, discharge and up to 24-month follow-up. Up to 1,000 patients may be enrolled at up to 50 study sites. Most of the enrollment will occur prospectively; however, the data collection for patients who already underwent a procedure with NBS may also take place retrospectively. For example, if the patient already had a NBS procedure, he/she may be approached about study participation. If the patient...
agrees to participate in the study, the data collection will be initiated once Informed Consent Form (ICF) is signed (e.g., demographics, procedure, and discharge data will be collected retrospectively and future follow-up visits collected prospectively).

3. Quality of Life after Surgery in Patients with Pituitary Tumors and Acromegaly – PI: Dr. Akagami - *New this quarter*

<table>
<thead>
<tr>
<th>Study period</th>
<th>Approvals</th>
<th>Anticipated Enrollment</th>
<th>Status</th>
<th>Abstract/Paper/Manuscript</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dec 2015 – Dec 2016</td>
<td>Approved</td>
<td>63</td>
<td>Ongoing</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Patients with pituitary tumors have been previously noted to report decreased quality of life (QoL). These studies have used a variety of validated questionnaires (such as SF36 and AcroQoL) to assess the physical, cognitive and psychological well-being of patients affected by functional and non-functional tumors. Predictably, QoL is variably affected by different types and extents of tumor. Studies which have focused on patients with acromegaly have generally shown improvement of QoL after treatment (GH<2ng/ml). However, it is not clear whether the improvement of QoL is primarily driven by the correction of hormonal imbalances. In fact, a recent study from Korea found that AcroQoL scores were similar between patients with controlled and uncontrolled disease.

This will be a retrospective review of QoL after pituitary surgery in patients with acromegaly. Any patient that lacks the SF36 questionnaire will be contacted, consented and given a copy to complete. All charts of patients who have previously undergone this procedure with Dr. Akagami shall be assessed. Multivariate analysis will be used to determine the factors which most impact QoL improvement post-operatively.
4. INACTIVE OR COMPLETE STUDIES

1. **Thromboprophylaxis in Traumatic Brain Injury Study** - an assessment of timing of treatment – PI: Dr Hameed - *Closed this quarter*

<table>
<thead>
<tr>
<th>Study period</th>
<th>Approvals UBC CREB/VCHRI</th>
<th>Charts reviewed /sample size</th>
<th>Status</th>
<th>Abstract/Paper/Manuscript</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apr. ’15 – ongoing</td>
<td>Obtained</td>
<td>351/351</td>
<td>Active</td>
<td>Pending</td>
<td>None</td>
</tr>
</tbody>
</table>

Timing of thromboprophylaxis following a traumatic brain injury (TBI) has been shown to be a contributing factor to complication rates and length of stay in TBI patients.

**Objective:**
- Determine optimal timing of thromboprophylaxis protocol implementation following a traumatic brain injury

The results from this study will assist in guiding the continual improvement of health care protocols, such as the one for thromboprophylaxis use following TBI.

The study has been approved by CREB and VCHRI.

2. **Perioperative Quality of Life in Patients with Cushing's Disease** – PI: Dr. Akagami - *Closed this quarter*

<table>
<thead>
<tr>
<th>Study period</th>
<th>Approvals UBC CREB/VCHRI</th>
<th>Charts reviewed /sample size</th>
<th>Status</th>
<th>Abstract/Paper/Manuscript</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>June 2015 – May 2017</td>
<td>Obtained</td>
<td>60/60</td>
<td>Active</td>
<td>Pending</td>
<td>None</td>
</tr>
</tbody>
</table>

**Objective:**

Our main objective is to investigate the cure rate for Cushing's Disease at Vancouver General Hospital. Because the recurrence rate is quite high, examining patient progress through the disease will elucidate the durability of surgical treatment. We will be indirectly measuring cure through patient quality of life. Examining quality of life will allow us to compare and contrast the efficacy of treatment with patient-centered outcomes.

Endogenous Cushing's Disease is a rare disorder with an annual incidence of 13 cases per million individuals. This rarity prevents medical centers from establishing universal management expertise in this disease. In particular, there have been no studies looking at patient quality of life as they progress through the disease. The quality of life is intricately affected by the complex nature of the disease. The project’s implications will be the first of its kind, and will elucidate the cure rate, and the durability of the cure in the management of CD, and draw a distinction between treatment efficacy and patient-centered outcome.

Vincent Ye was a summer student who had obtained UBC SSRP funding for the summer.

3. **Timing of Incidence and Recovery of Delayed Facial Palsy after vestibular schwannoma resection: a retrospective review** – PI: Dr. Akagami - *Closed this quarter*
Preservation of facial nerve function during resection of vestibular schwannomas (VS) remains one of the most important goals of surgery, with a significant impact on patient satisfaction and quality of life post-operatively\(^1\). Delayed facial palsy (DFP) is a well-described, but incompletely understood phenomenon in which patients develop facial nerve palsy several days after surgical resection of VS\(^2\). Several postulations have been made about the etiology of DFP, although none can satisfactorily explain all of the major features of this palsy. The purpose of this retrospective review is to examine our institution’s large series of data regarding the timing of DFP onset and recovery, in order to draw inferences about the neural pathophysiology of this disorder. The study has been approved by CREB/VCHRI and the chart review is in progress.
5. SUMMER STUDENTS

1. Collection and Submission of Clinical, CSF and Radiological Data of Patients Being Assessed at Vancouver General Hospital Adult Hydrocephalus Clinic as Part of the Adult Hydrocephalus Clinical Research Network (AHCORN)

PI: Dr. Charles Haw
Student: Mr. Nicholas Salterio, Y1 B.Sc.
Project Supervisor: Dr. Thomas J. Zwimpfer
Funding: VGH Foundation Hydrocephalus Fund